| Company | Date | Position | Consensus β | Price Target β | 2-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
INSM
Insmed
|
Oct 29, 2026 | BUY |
Strong Buy
+51.3% avg upside
37 analysts
|
$204.00
81.14% Upside
|
+9.2% | Β· |
|
EQ
Equillium
|
Oct 27, 2026 | BUY |
Strong Buy
+585.1% avg upside
16 analysts
|
$12.00
775.85% Upside
|
-11.0% | Β· |
|
DNTH
Dianthus Therapeutics
|
Oct 27, 2026 | BUY |
Strong Buy
+23.4% avg upside
32 analysts
|
$113.00
37.20% Upside
|
+9.4% | Β· |
|
VTVT
vTv Therapeutics
|
Oct 21, 2026 | BUY |
Strong Buy
+50.1% avg upside
14 analysts
|
$58.00
130.51% Upside
|
-37.7% | Β· |
|
OSTX
OS Therapies Incorporated
|
Oct 06, 2026 | BUY |
Strong Buy
+803.2% avg upside
5 analysts
|
$7.00
464.43% Upside
|
-54.3% | Β· |
|
ARCT
Arcturus Therapeutics
|
Sep 24, 2026 | BUY |
Buy
+175.6% avg upside
36 analysts
|
$41.00
271.68% Upside
|
-40.8% | Β· |
|
BIOA
BioAge Labs, Inc.
|
Sep 09, 2026 | BUY |
Strong Buy
+506.9% avg upside
9 analysts
|
$25.00
325.97% Upside
|
-44.4% | Β· |
|
RARE
Ultragenyx Pharmaceutical
|
May 18, 2020 | BUY |
Strong Buy
+193.8% avg upside
36 analysts
|
$82.00
409.25% Upside
|
-34.3% | Β· |
|
ASND
Ascendis Pharma
|
Apr 20, 2020 | BUY |
Strong Buy
+12.3% avg upside
29 analysts
|
$171.00
31.87% Downside
|
-20.9% | Β· |
|
LKFT
Lakefront Biotherapeutics
|
Apr 08, 2020 | BUY |
Buy
+217.3% avg upside
25 analysts
|
$298.00
823.19% Upside
|
-65.4% | Β· |
|
CORT
Corcept Therapeutics
|
Feb 10, 2020 | HOLD |
Buy
-17.9% avg upside
16 analysts
|
β | +39.9% | Β· |
|
KYNB
Kyntra Bio
|
Nov 12, 2019 | BUY |
Buy
+615.9% avg upside
17 analysts
|
$71.00
1453.61% Upside
|
Β· | Β· |
|
ALDX
Aldeyra Therapeutics
|
Jun 25, 2019 | BUY |
Strong Buy
+2746.2% avg upside
21 analysts
|
$25.00
4361.80% Upside
|
+84.7% | Β· |
|
PTGX
Protagonist Therapeutics
|
May 08, 2019 | BUY |
Strong Buy
-17.0% avg upside
19 analysts
|
$17.00
88.32% Downside
|
+205.9% | Β· |
|
EOCN
Eocene
|
Nov 05, 2018 | BUY |
Buy
+688.3% avg upside
13 analysts
|
$35.00
1029.03% Upside
|
Β· | Β· |
|
VRTX
Vertex Pharmaceuticals
|
Jul 18, 2017 | BUY |
Strong Buy
-20.5% avg upside
62 analysts
|
$182.00
67.41% Downside
|
+34.8% | Β· |
|
BMRN
BioMarin Pharmaceutical
|
Mar 03, 2016 | BUY |
Strong Buy
+63.6% avg upside
52 analysts
|
$107.00
82.81% Upside
|
-10.8% | Β· |
|
TSE:BHC
Bausch Health Companies
|
Nov 30, 2015 | BUY |
Buy
+386.9% avg upside
30 analysts
|
$223.43
1847.89% Upside
|
-81.9% | Β· |
|
ALNY
Alnylam Pharma
|
Jun 24, 2015 | BUY |
Strong Buy
+76.3% avg upside
53 analysts
|
$160.00
3.06% Downside
|
-31.1% | Β· |
|
SRPT
Sarepta Therapeutics
|
May 20, 2015 | BUY |
Buy
+223.8% avg upside
50 analysts
|
$30.00
61.08% Upside
|
+32.0% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.